Aktionärsstruktur

Inhaber in %
Freefloat 99,83
PRIMECAP Management Co. 9,58
Vanguard Group, Inc. (Subfiler) 7,41
The Vanguard Group, Inc. 7,36
Vanguard PRIMECAP Fund 5,60
State Street Corp. 4,80
BlackRock Fund Advisors 3,13
Wellington Management Co. LLP 2,93
Vanguard Total Stock Market Index Fund 2,80
BlackRock Institutional Trust Co. NA 2,53
ClearBridge Investments LLC 2,50
Renaissance Technologies LLC 2,39
Vanguard Health Care Fund 2,28
Vanguard 500 Index Fund 2,05
Geode Capital Management LLC 1,86

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2015 2016 2017 2018 2019
Personal am Ende des Jahres 7.350 7.400 7.300 7.800 7.400
Umsatz pro Mitarbeiter in Mio. EUR 1,27 1,38 1,51 1,55 1,72

Bilanz (in Mio. EUR) - Aktiva

2015 2016 2017 2018 2019
Summe Umlaufvermögen 6.700 8.732 7.873 7.641 8.382
Summe Anlagevermögen 15.899 18.658 18.551 18.976 19.784
Summe Aktiva 19.505 22.877 23.653 25.289 27.234

Bilanz (in Mio. EUR) - Passiva

2015 2016 2017 2018 2019
Gesamtverschuldung/ -verbindlichkeiten 6.526 6.517 5.938 5.937 6.441
Summe Fremdkapital 10.130 10.748 11.055 12.257 13.895
Summe Eigenkapital 9.375 12.129 12.598 13.032 13.339
Summe Passiva 19.505 22.877 23.653 25.289 27.234

Adresse

225 Binney Street, 02142 Cambridge
Telefon +1 (617) 679-2000
Internet http://www.biogen.com

Management

Alexander John Denner
Independent Director
Alfred W. Sandrock
Chief Medical Officer & EVP-Research & Development
Alisha A. Alaimo
Senior Vice President & Head-US Organization
Alphonse Galdes
EVP-Pharmaceutical Operations & Technology
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences
Brian S. Posner
Independent Director
Caroline D. Dorsa
Independent Director
Chirfi Guindo
Executive Vice President & Head-Global Marketing
Daniel Karp
Executive Vice President-Corporate Development
Ed Dondero
Director-Real Estate & Planning
Eric K. Rowinsky
Independent Director
Fanny Cavalié
Head-Multiple Sclerosis Portfolio Strategy
Ginger Gregory
Chief Human Resources Officer & Executive VP
Jacob Elkins
Vice President & Head-Acute Neurology Research
Jesse M. Cedarbaum
VP-Neurology Early Clinical Development
Jesus B. Mantas
Independent Director
Mark Hernon
Chief Information Officer & Senior Vice President
Michael R. McDonnell
Chief Financial Officer & Executive Vice President
Michel Vounatsos
Chief Executive Officer & Director
Nancy L. Leaming
Independent Director
Philipp Von Rosenstiel
Senior Medical Director--Alzheimers & Dementia
Richard A. Rudick
Vice President-Development Sciences
Richard Charles Mulligan
Independent Director
Robert W. Pangia
Independent Director
Robin C. Kramer
Chief Accounting Officer & Vice President
Rohin Mhatre
Senior VP-Product & Technology Development
Sanjay Jariwala
Senior Vice President & Head-Worldwide Medical
Simon Nicholas Tate
Head-Covergence Development Team
Stelios B. Papadopoulos
Chairman
Stephen A. Sherwin
Independent Director
Susan H. Alexander
Secretary, Chief Legal Officer & Executive VP
Wildon R. Farwell
Senior Medical Director-Clinical Development
William A. Hawkins
Independent Director